PSYCH Investor Summit: Research & Development - Company Presentation: Gwella Mushrooms

Описание: Gwella Mushrooms – Company Presentation and Overview. At the 7 July PSYCH Investor Summit: Research & Development, Gwella’s Chief Scientific Officer, Daniel Sanders, and Co-founder and Director of Product, Erin Cochrane, outlined the company’s product portfolio, ambitions and vision for the future.

About Erin Cochrane, Co-founder and Director of Product at Gwella Mushrooms:

As Co-founder and Director of Product at Gwella Mushrooms, Erin develops product strategies around current scientific understanding, market trends, community needs and specific health use cases

About Daniel Sanders, Chief Scientific Officer at Gwella Mushrooms:

Daniel has a decade of experience researching medicinal mushrooms, biohacking, and cannabis extraction. He graduated from the University of Arkansas at Little Rock for molecular biotechnology with an emphasis in genetics.

About PSYCH:

PSYCH is a premium business-to-business media and content platform for the psychedelic science and healthcare industry.

The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace.

We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.

To learn more about us, access our industry-leading events, subscribe to the most widely read psychedelics industry newsletter, or view our insight-rich Psychedelics as Medicine Report.

Web: https://psych.global/
Twitter:   / psychglobal_  
LinkedIn:   / psych%e2%84%a2